Cargando…

Novel Therapies for Aggressive B-Cell Lymphoma

Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foon, Kenneth A., Takeshita, Kenichi, Zinzani, Pier L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318210/ https://www.ncbi.nlm.nih.gov/pubmed/22536253 http://dx.doi.org/10.1155/2012/302570

Ejemplares similares

Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Molecular Profiling of Aggressive Lymphomas
por: Rossi, Maura, et al.
Publicado: (2012)

Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma
por: Morgan, Elizabeth A., et al.
Publicado: (2012)

Lymphoma immunotherapy
por: Zinzani, Pier Luigi
Publicado: (2018)

Aggressive B-Cell Lymphomas
por: Naresh, Kikkeri N., et al.
Publicado: (2012)

Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas
por: Cacciatore, Matilde, et al.
Publicado: (2012)

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas
por: Wang, Michelle Y., et al.
Publicado: (2021)

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2019)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
por: Myers, G Doug, et al.
Publicado: (2021)

Genetic background and evolution of relapses in aggressive B-cell lymphomas
por: Juskevicius, Darius, et al.
Publicado: (2017)

Novel and emerging therapies for B cell lymphoma
por: Ayyappan, Sabarish, et al.
Publicado: (2019)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016)

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Molecular classification of aggressive B-cell lymphoma
por: Bojarczuk, Kamil, et al.
Publicado: (2019)

New Treatment Options in Advanced Stage Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2018)

Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
por: Gao, Jing, et al.
Publicado: (2021)

Nuances in the Management of Aggressive Lymphomas
por: Hamlin, Paul A., et al.
Publicado: (2017)

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
por: Agostinelli, C, et al.
Publicado: (2008)

Oncogenic Properties of Apoptotic Tumor Cells in Aggressive B Cell Lymphoma
por: Ford, Catriona A., et al.
Publicado: (2015)

MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management
por: Cai, Qingqing, et al.
Publicado: (2015)

Autologous Stem Cell Transplantation for Aggressive Lymphomas
por: Visani, Giuseppe, et al.
Publicado: (2012)

Epigenetics, c-Myc and Aggressive B-cell Lymphomas
por: Zhang, Yizhuo, et al.
Publicado: (2012)

Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas
por: Tadiotto Cicogna, Giulia, et al.
Publicado: (2019)

The International Prognostic Index in aggressive B-cell lymphoma
por: Maurer, Matthew J.
Publicado: (2023)

Renal Lymphoma: Primary or First Manifestation of Aggressive Pediatric B-cell Lymphoma
por: Coca, Pragnya, et al.
Publicado: (2017)

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
por: Volpetti, Stefano, et al.
Publicado: (2014)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Aggressive B-cell lymphoma subtyping: a pathologists viewpoint
por: de Jong, Daphne
Publicado: (2019)

Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
por: Chang, Kung-Chao, et al.
Publicado: (2020)

The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Diffuse large B-cell lymphoma: new targets and novel therapies
por: Cheson, Bruce D., et al.
Publicado: (2021)

A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma
por: Sethi, Ashish K, et al.
Publicado: (2021)

The importance of assessing blood tumour burden in cutaneous T‐cell lymphoma
por: Vermeer, M.H., et al.
Publicado: (2021)

PB2137: INFLUENCE OF PREVIOUS RADIOTHERAPY ON THE EFFECT OF CART CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA
por: Shaomei, F.
Publicado: (2022)

Management of central nervous system relapse in a young patient affected by primary mediastinal large B‐cell lymphoma: A case report
por: Marangon, Miriam, et al.
Publicado: (2020)

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review
por: Khanmohammadi, Shaghayegh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_guom40t1a29relndlvfv5ir6s1